← All trials
NCT00097110
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2003
- Primary completion
- —
- Completion date
- Dec 1, 2006
- First posted
- —
- Last posted
- —
- Enrollment
- 734
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- National Institute of Child Health and Human Development (NICHD)Lead sponsor
- University of CincinnatiOverall official - principal investigator
- National Center for Complementary and Integrative Health (NCCIH)Collaborator
- National Institute of Dental and Craniofacial Research (NIDCR)Collaborator
- National Cancer Institute (NCI)Collaborator
- RTI InternationalCollaborator
- University of CincinnatiCollaborator
- Federal University of PernambucoCollaborator
- Federal University of Rio Grande do SulCollaborator
- University of CampinasCollaborator
- Bill and Melinda Gates FoundationCollaborator
- Faculdade de Medicina de BotucatuCollaborator
- University of Sao PauloCollaborator
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.